Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals is a development stage biopharmaceutical company devoted to finding breakthrough therapies for cancer patients.

With proven records of the management team in guiding molecules from early stage of clinical development to successful worldwide approvals, we offer large pharmaceutical drug development expertise in conjunction with the agility and speed of a small organization.

May 1, 2009 - First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418 » Read

April 30, 2009 - Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting » Read

April 20, 2009 - Karmanos Cancer Institute researchers present breast cancer advancements at conference » Read

April 16, 2009 - Tigris Pharmaceuticals Appoints Pedro Granadillo as Chairman of Board of Directors » Read


	AACR Annual Meeting 2008 April 12-16, 2008 San Diego, CA Oral Presentation of Aminoflavone "Breast cancer cells resistant to anti-hormone treatments retain sensitivity to Aminoflavone (NSC 686288)"